Randomized trial of Covid-19 chemoprophylaxis in healthcare professionals (COVIDAXIS trial)

  • Funded by Institut Pasteur International Network (IPIN)
  • Total publications:0 publications

Grant number: COVIDAXIS trial

Grant search

Key facts

  • Disease

  • Funder

    Institut Pasteur International Network (IPIN)
  • Principle Investigator

  • Research Location

  • Lead Research Institution

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Clinical trials for disease management

  • Special Interest Tags


  • Study Subject


  • Clinical Trial Details

    Randomized Controlled Trial

  • Broad Policy Alignment


  • Age Group

    Adults (18 and older)

  • Vulnerable Population


  • Occupations of Interest

    Hospital personnelUnspecified


Objective: To determine whether a two months treatment with hydroxychloroquine (HCQ) or Lopinavir / ritonavir (LPV / r) reduces the incidence of symptomatic or asymptomatic infections with SARS-CoV-2, compared to their placebo, in healthcare professionals exposed to the virus.In the absence of specific antiviral treatment, particular attention must be paid to prevention. Individual protective equipment can be insufficiently protective, including for healthcare professionals.If this trial confirms the efficacy of either drug, a chemoprophylaxis strategy could be extended to other populations highly exposed to SARS-CoV-2 or at risk of severe forms of Covid-19 while waiting for other preventive tools, vaccines in particular, to become available.